StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
IBAI.L$0.63+0.00%
Fair $0.63+0.0%

IBAI.L

Imaging Biometrics Ltd.

Healthcare / Health Information ServicesLSE

$0.63

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.63Fund rank 26/100 · Data gapFallback financials|
SA 17/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-190061.00 · quality 54.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 34/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -98.4%, below the 5% threshold
Thesis & Journal · IBAI.LLocal privado en este navegador · Imaging Biometrics Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-98.4%

↓

Gross Margin

93.5%

↑

Debt/Equity

N/A

•
52-Week Range$1
$0$1

TradingView lightweight chart

IBAI.L price, volumen y niveles de valoración

Último $0.625Periodo -99.5%
Fair value: $0.625

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+13.7%

FCF CAGR

—

FCF margin

-24.1%

FCF / Net income

0.47x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $788148.0 · net income $-400940.0 · FCF $-190061.0

2022-FY → 2025-FY

Gross margin

93.5%-6.1% pts

Operating margin

-19.9%+73.5% pts

Net margin

-50.9%+44.6% pts

FCF margin

-24.1%+53.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$788148.00$788148.00$750105.00$609390.00$535886.00
Net Income$-400940.00$-400940.00$-327103.00$-623816.00$-511601.00
EBITDA$-307456.00$-307456.00$-273039.00$-498550.00$-360284.00
EPS-0.00-0.00-0.00-0.00-0.00
Gross Margin93.5%93.5%99.0%98.1%99.7%
Operating Margin-19.9%-19.9%-43.7%-66.7%-93.5%
Net Margin-50.9%-50.9%-43.6%-102.4%-95.5%
Balance Sheet
Current Ratio0.550.55———
Cash Flow
Free Cash Flow$-190061.00$-190061.00$-445141.00$-175234.00$-414601.00
Returns
ROE-98.4%-98.4%-108.1%-657.2%-72.4%
Valuation
P/B410.86410.861107.419632.60482.16
Growth & Yield
Revenue Growth5.1%5.1%23.1%13.7%—
EPS Growth-13.3%-13.3%55.9%-21.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -21.9%

Total return

-21.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.00 → -0.00

Residual

-21.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-21.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.